Viatris slumps after weaker-than-expected earnings forecast

** Shares of generic drugmaker Viatris VTRS fall 11.3% to $9.97 premarket

** Co forecast 2025 revenue to be between $13.5 bln and $14 bln, below analysts' est of $14.27 bln - LSEG

** Co expects 2025 adj profit between $2.12/shr and $2.26/shr, compared with estimates of $2.59/shr - LSEG

** VTRS says it estimates FDA action will negatively impact its 2025 total revenues by about $500 mln and adjusted core earnings by roughly $385 mln.

** Last year, FDA has restricted imports from Viatris' Indore facility in India due to regulatory violations

** Co also reports Q4 adj profit of 54 cents/shr, below analysts' est of 57 cents/shr - LSEG

** Co posts Q4 sales of $3.52 bln, below analysts' est of $3.61 bln - LSEG

** VTRS gained 8.6% in 2024